Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection.

Anti-HIV Agents / therapeutic use Emtricitabine / therapeutic use HIV HIV Infections / drug therapy Humans Immunoassay Medication Adherence Pre-Exposure Prophylaxis Tenofovir / therapeutic use
PrEP ELISA HIV prevention immunoassay urine

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
01 02 2021
Historique:
received: 07 02 2020
accepted: 17 06 2020
entrez: 2 2 2021
pubmed: 3 2 2021
medline: 29 4 2021
Statut: ppublish

Résumé

New tools are needed to support pre-exposure prophylaxis (PrEP) adherence for human immunodeficiency virus (HIV) prevention, including those that enable real-time feedback. In a large, completed PrEP trial, adequate urine tenofovir levels measured using a novel immunoassay predicted HIV protection and showed good sensitivity and specificity for detectable plasma tenofovir.

Identifiants

DOI: 10.1093/cid/ciaa785 PMID: 33527128 PMC: PMC7850546
pubmed: 33527128
pii: 5860911
doi: 10.1093/cid/ciaa785
pmc: PMC7850546
doi:

Substances chimiques

Anti-HIV Agents 0
Tenofovir 99YXE507IL
Emtricitabine G70B4ETF4S

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

486-489

Subventions

Organisme : NIAID NIH HHS
ID : T32 AI007140
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI094189
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI143340
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027763
Pays : United States
Organisme : NIMH NIH HHS
ID : K23 MH122286
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI060530
Pays : United States

Investigateurs

Connie Celum (C)
Jared M Baeten (JM)
Deborah Donnell (D)
Robert W Coombs (RW)
Jairam R Lingappa (JR)
M Juliana McElrath (MJ)
Kenneth H Fife (KH)
Edwin Were (E)
Elioda Tumwesigye (E)
Patrick Ndase (P)
Elly Katabira (E)
Elly Katabira (E)
Allan Ronald (A)
Elizabeth Bukusi (E)
Craig R Cohen (CR)
Jonathan Wangisi (J)
James D Campbell (JD)
Jordan W Tappero (JW)
James Kiarie (J)
Carey Farquhar (C)
Grace John-Stewart (G)
Nelly R Mugo (NR)
Kenneth Ngure (K)
James D Campbell (JD)
Jordan W Tappero (JW)
Jonathan Wangisi (J)

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

AIDS Care. 2019 Oct;31(10):1203-1206
pubmed: 30821473
J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):340-8
pubmed: 24784763
Clin Infect Dis. 2020 May 6;70(10):2143-2151
pubmed: 31314073
Curr Opin HIV AIDS. 2016 Jan;11(1):10-7
pubmed: 26633638
J Acquir Immune Defic Syndr. 2019 Nov 1;82(3):252-256
pubmed: 31335590
AIDS. 2020 Feb 1;34(2):255-260
pubmed: 31634188
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
J Acquir Immune Defic Syndr. 2019 May 1;81(1):72-77
pubmed: 30664078
HIV Med. 2017 Jul;18(6):412-418
pubmed: 28444867
AIDS. 2016 Jul 31;30(12):1973-83
pubmed: 27149090
AIDS. 2019 Apr 1;33(5):867-872
pubmed: 30649051
Sex Transm Infect. 2018 May;94(3):163-168
pubmed: 28756409

Auteurs

Randy M Stalter (RM)

Department of Global Health, University of Washington, Seattle, Washington, USA.
Department of Epidemiology, University of Washington, Seattle, Washington, USA.

Jared M Baeten (JM)

Department of Global Health, University of Washington, Seattle, Washington, USA.
Department of Epidemiology, University of Washington, Seattle, Washington, USA.
Department of Medicine, University of Washington, Seattle, Washington, USA.

Deborah Donnell (D)

Department of Global Health, University of Washington, Seattle, Washington, USA.
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Matthew A Spinelli (MA)

Division of HIV, ID, and Global Medicine, University of California-San Francisco, San Francisco, California, USA.

David V Glidden (DV)

Division of HIV, ID, and Global Medicine, University of California-San Francisco, San Francisco, California, USA.

Warren C Rodrigues (WC)

Toxicology Division, Abbott Rapid Diagnostics, Pomona, California, USA.

Guohong Wang (G)

Toxicology Division, Abbott Rapid Diagnostics, Pomona, California, USA.

Michael Vincent (M)

Toxicology Division, Abbott Rapid Diagnostics, Pomona, California, USA.

Nelly Mugo (N)

Department of Global Health, University of Washington, Seattle, Washington, USA.
Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.

Andrew Mujugira (A)

Department of Global Health, University of Washington, Seattle, Washington, USA.
Infectious Diseases Institute, Makerere University, Kampala, Uganda.

Mark Marzinke (M)

Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.

Craig Hendrix (C)

Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.

Monica Gandhi (M)

Division of HIV, ID, and Global Medicine, University of California-San Francisco, San Francisco, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Antirétroviraux › Agents antiVIH › Urine Tenofovir Levels Measured Using a Novel...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Nucléosides pyrimidiques › Désoxycytidine › Emtricitabine › Urine Tenofovir Levels Measured Using a Novel...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Lentivirus › Lentivirus des primates › VIH (Virus de l'Immunodéficience Humaine) › Urine Tenofovir Levels Measured Using a Novel...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Urine Tenofovir Levels Measured Using a Novel...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Urine Tenofovir Levels Measured Using a Novel...
questionsmedicales.fr › Techniques d'investigation › Techniques de sonde moléculaire › Dosage immunologique › Urine Tenofovir Levels Measured Using a Novel...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Prestations des soins de santé › Attitude envers la santé › Adhésion et observance thérapeutiques › Acceptation des soins par les patients › Observance par le patient › Adhésion au traitement médicamenteux › Urine Tenofovir Levels Measured Using a Novel...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Prophylaxie pré-exposition › Urine Tenofovir Levels Measured Using a Novel...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Purines › Adénine › Ténofovir › Urine Tenofovir Levels Measured Using a Novel...